• See Also
  1. Tuberculosis
  2. Latent Tuberculosis Treatment
  3. Active Tuberculosis Treatment
  4. Susceptible Tuberculosis Treatment
  5. Multiple Drug Resistant Tuberculosis Treatment
  6. Tuberculosis Screening in Children
  7. Tuberculosis Risk Factors (Tuberculosis Screening Indications)
  8. Tuberculosis Risk Factors for progression from Latent to Active Disease (Latent Tuberculosis Treatment Indications)
  9. Tuberculosis Related Chest XRay Changes
  10. Extrapulmonary Tuberculosis
  11. Tuberculin Skin Test (TST, Purified Protein Derivative, PPD)
  12. Mycobacterium Tuberculosis Antigen-Specific Interferon-Gamma Release Assay (IGRA)
  13. Tuberculosis Resources
  • Indications
  1. Isoniazid Resistance >4% in patient's community
  2. Human Immunodeficiency Virus (HIV)
  3. Prior Tuberculosis exposure
  • Precautions
  1. This protocol is from 2003 without available new guidance to use for update as of 2016 review
  2. Multi-drug resistance requires expert local infectious disease opinion for guidance
  • Management
  1. Initial: Four drug therapy for 2 months
    1. Isoniazid
    2. Rifampin
    3. Pyrazinamide
    4. Ethambutol or Streptomycin
  2. Subsequent Dosing
    1. If Isoniazid susceptible, treat for 6 months
      1. Isoniazid
      2. Rifampin
    2. If Isoniazid resistant THEN
      1. Protocol A: Treat for 6 months
        1. Rifampin
        2. Pyrazinamide AND
        3. Ethambutol OR Streptomycin
      2. Protocol B: Treat for 12 months
        1. Rifampin
        2. Ethambutol
    3. If Extrapulmonary Tuberculosis, treat for >9 months
      1. Disseminated tuberculosis
      2. Osteomyelitis
      3. Meningitis
      4. Human Immunodeficiency Virus (HIV)
    4. If TuberculosisMeningitis
      1. Continue Pyrazinamide for full course